外周渗出出血性脉络膜视网膜病变(PEHCR)突破性玻璃体出血的临床特点及治疗效果。

Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-08-19 eCollection Date: 2025-01-01 DOI:10.2147/OPTH.S535257
Thanaporn Kritfuangfoo, Yanliang Li, William F Mieler
{"title":"外周渗出出血性脉络膜视网膜病变(PEHCR)突破性玻璃体出血的临床特点及治疗效果。","authors":"Thanaporn Kritfuangfoo, Yanliang Li, William F Mieler","doi":"10.2147/OPTH.S535257","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the clinical characteristics and treatment outcomes of breakthrough vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy (PEHCR).</p><p><strong>Methods: </strong>This retrospective study included 14 eyes from 14 patients with vitreous hemorrhage secondary to peripheral retinochoroidal mass lesions. Data collected included demographic profiles, clinical presentation, multimodal imaging findings, and treatment outcomes following pars plana vitrectomy (PPV), intravitreal anti-VEGF injections, or laser photocoagulation.</p><p><strong>Results: </strong>The median age at presentation was 83 years (range, 58-91), with nine females (64.3%). Median presenting visual acuity (VA) was 1.3 logMAR (range, 0.3-2.7). All patients had normal intraocular pressure. Bilateral PEHCR was observed in 50%, though hemorrhage occurred unilaterally. Unifocal lesions were present in 71.4%, with a mean lesion thickness of 3.4 mm (range, 1.5-6.8 mm). Dense vitreous hemorrhage obscuring posterior pole details was seen in eight eyes (57.1%) and required PPV. The remaining six eyes, with moderate hemorrhage, improved spontaneously without surgery. Intravitreal anti-VEGF therapy was administered in five eyes for macular involvement or to prevent recurrent hemorrhage. At a median follow-up of 11.7 months (range, 3-63), median VA improved to 0.36 logMAR (range, 0.1-2.0). The mean VA gain was 0.76 logMAR in the vitrectomy group (p = 0.004) and 0.55 logMAR in eyes without macular involvement (p = 0.024). However, five eyes (35.7%) had final VA ≤ 20/200 due to macular pathology consistent with age-related macular degeneration or polypoidal choroidal vasculopathy-like changes.</p><p><strong>Conclusion: </strong>PEHCR with breakthrough vitreous hemorrhage is a rare but important diagnostic consideration in patients presenting with peripheral retinochoroidal mass-like lesions. PPV and intravitreal anti-VEGF therapy may improve visual outcomes in these cases. However, visual recovery may be limited in cases with macular involvement due to irreversible retinal damage. Early diagnosis and tailored management are essential to optimize outcomes and avoid misdiagnosis.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2821-2833"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374697/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Characteristics and Treatment Outcomes of Breakthrough Vitreous Hemorrhage in Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR).\",\"authors\":\"Thanaporn Kritfuangfoo, Yanliang Li, William F Mieler\",\"doi\":\"10.2147/OPTH.S535257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the clinical characteristics and treatment outcomes of breakthrough vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy (PEHCR).</p><p><strong>Methods: </strong>This retrospective study included 14 eyes from 14 patients with vitreous hemorrhage secondary to peripheral retinochoroidal mass lesions. Data collected included demographic profiles, clinical presentation, multimodal imaging findings, and treatment outcomes following pars plana vitrectomy (PPV), intravitreal anti-VEGF injections, or laser photocoagulation.</p><p><strong>Results: </strong>The median age at presentation was 83 years (range, 58-91), with nine females (64.3%). Median presenting visual acuity (VA) was 1.3 logMAR (range, 0.3-2.7). All patients had normal intraocular pressure. Bilateral PEHCR was observed in 50%, though hemorrhage occurred unilaterally. Unifocal lesions were present in 71.4%, with a mean lesion thickness of 3.4 mm (range, 1.5-6.8 mm). Dense vitreous hemorrhage obscuring posterior pole details was seen in eight eyes (57.1%) and required PPV. The remaining six eyes, with moderate hemorrhage, improved spontaneously without surgery. Intravitreal anti-VEGF therapy was administered in five eyes for macular involvement or to prevent recurrent hemorrhage. At a median follow-up of 11.7 months (range, 3-63), median VA improved to 0.36 logMAR (range, 0.1-2.0). The mean VA gain was 0.76 logMAR in the vitrectomy group (p = 0.004) and 0.55 logMAR in eyes without macular involvement (p = 0.024). However, five eyes (35.7%) had final VA ≤ 20/200 due to macular pathology consistent with age-related macular degeneration or polypoidal choroidal vasculopathy-like changes.</p><p><strong>Conclusion: </strong>PEHCR with breakthrough vitreous hemorrhage is a rare but important diagnostic consideration in patients presenting with peripheral retinochoroidal mass-like lesions. PPV and intravitreal anti-VEGF therapy may improve visual outcomes in these cases. However, visual recovery may be limited in cases with macular involvement due to irreversible retinal damage. Early diagnosis and tailored management are essential to optimize outcomes and avoid misdiagnosis.</p>\",\"PeriodicalId\":93945,\"journal\":{\"name\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"volume\":\"19 \",\"pages\":\"2821-2833\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374697/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/OPTH.S535257\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S535257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨外周渗出性出血性脉络膜视网膜病变(PEHCR)继发突破性玻璃体出血的临床特点及治疗效果。方法:对14例视网膜周围脉络膜肿块继发玻璃体出血患者的14只眼进行回顾性研究。收集的数据包括人口统计资料、临床表现、多模态成像结果,以及玻璃体切除术(PPV)、玻璃体内抗vegf注射或激光光凝治疗后的治疗结果。结果:患者的中位年龄为83岁(范围58-91岁),其中9例为女性(64.3%)。中位表现视力(VA)为1.3 logMAR(范围0.3-2.7)。所有患者眼压正常。50%的患者出现双侧PEHCR,但单侧出血。71.4%为单灶性病变,平均厚度3.4 mm(范围1.5-6.8 mm)。8只眼(57.1%)可见致密玻璃体出血模糊后极细节,需要PPV。其余6只眼睛,有中度出血,无需手术自行好转。玻璃体内抗vegf治疗在五只眼黄斑受损伤或防止复发性出血。在中位随访11.7个月(范围3-63)时,中位VA改善至0.36 logMAR(范围0.1-2.0)。玻璃体切除组的平均VA增益为0.76 logMAR (p = 0.004),未受累黄斑眼的平均VA增益为0.55 logMAR (p = 0.024)。然而,由于黄斑病变符合年龄相关性黄斑变性或息肉样脉络膜血管病变样改变,5只眼(35.7%)最终VA≤20/200。结论:PEHCR伴突破性玻璃体出血是一种罕见但重要的诊断因素。PPV和玻璃体内抗vegf治疗可改善这些病例的视力。然而,由于不可逆的视网膜损伤,在黄斑受累的情况下,视力恢复可能受到限制。早期诊断和量身定制的管理对于优化结果和避免误诊至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Clinical Characteristics and Treatment Outcomes of Breakthrough Vitreous Hemorrhage in Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR).

Clinical Characteristics and Treatment Outcomes of Breakthrough Vitreous Hemorrhage in Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR).

Clinical Characteristics and Treatment Outcomes of Breakthrough Vitreous Hemorrhage in Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR).

Clinical Characteristics and Treatment Outcomes of Breakthrough Vitreous Hemorrhage in Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR).

Purpose: To evaluate the clinical characteristics and treatment outcomes of breakthrough vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy (PEHCR).

Methods: This retrospective study included 14 eyes from 14 patients with vitreous hemorrhage secondary to peripheral retinochoroidal mass lesions. Data collected included demographic profiles, clinical presentation, multimodal imaging findings, and treatment outcomes following pars plana vitrectomy (PPV), intravitreal anti-VEGF injections, or laser photocoagulation.

Results: The median age at presentation was 83 years (range, 58-91), with nine females (64.3%). Median presenting visual acuity (VA) was 1.3 logMAR (range, 0.3-2.7). All patients had normal intraocular pressure. Bilateral PEHCR was observed in 50%, though hemorrhage occurred unilaterally. Unifocal lesions were present in 71.4%, with a mean lesion thickness of 3.4 mm (range, 1.5-6.8 mm). Dense vitreous hemorrhage obscuring posterior pole details was seen in eight eyes (57.1%) and required PPV. The remaining six eyes, with moderate hemorrhage, improved spontaneously without surgery. Intravitreal anti-VEGF therapy was administered in five eyes for macular involvement or to prevent recurrent hemorrhage. At a median follow-up of 11.7 months (range, 3-63), median VA improved to 0.36 logMAR (range, 0.1-2.0). The mean VA gain was 0.76 logMAR in the vitrectomy group (p = 0.004) and 0.55 logMAR in eyes without macular involvement (p = 0.024). However, five eyes (35.7%) had final VA ≤ 20/200 due to macular pathology consistent with age-related macular degeneration or polypoidal choroidal vasculopathy-like changes.

Conclusion: PEHCR with breakthrough vitreous hemorrhage is a rare but important diagnostic consideration in patients presenting with peripheral retinochoroidal mass-like lesions. PPV and intravitreal anti-VEGF therapy may improve visual outcomes in these cases. However, visual recovery may be limited in cases with macular involvement due to irreversible retinal damage. Early diagnosis and tailored management are essential to optimize outcomes and avoid misdiagnosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信